Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Third Quarter 2024 Financial ...
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies ...
Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update
NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact ...
Daily3 天
Transcatheter tricuspid valve replacement effective in patients with severe tricuspid ...
A new study published in the New England Journal of Medicine showed that improvements in symptoms and quality of life were ...
Too Old to Operate4 天
RHEIA: TAVI Preferred Over Surgery in Women With Aortic Stenosis
The RHEIA trial studied women with severe aortic stenosis and found that participants preferred transcatheter aortic valve replacement over surgical valve replacement.